Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exploiting structural principles to design cyclin-dependent kinase inhibitors.

Martin Noble1, Paul Barrett, Jane Endicott

  • 1Laboratory of Molecular Biophysics and Department of Biochemistry, The Rex Richards Building, South Parks Road, Oxford, OX1 3QU, UK. martin.noble@biop.ox.ac.uk

Biochimica Et Biophysica Acta
|December 20, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying research priorities for post-collision care in the United Kingdom: outcomes and methodological adaptations from the final prioritisation workshop.

Scandinavian journal of trauma, resuscitation and emergency medicine·2026
Same author

Exposure risk of alcids to marine vessel-associated oil pollution in Western Canada.

The Science of the total environment·2026
Same author

Root-derived allelochemicals from <i>Moringa oleifera</i> regulate germination and early seedling growth in New Zealand pasture, native, and weed species.

Plant signaling & behavior·2026
Same author

The effect of robot-assisted gait training on physical activity outcomes in people with spinal cord injury: A systematic review.

Clinical rehabilitation·2026
Same author

Trapped and traumatised: a scoping review of the psychological sequelae of entrapment following motor vehicle collision.

Scandinavian journal of trauma, resuscitation and emergency medicine·2026
Same author

Identifying research priorities for post-collision care in the United Kingdom: protocol for a road injury priority setting partnership.

Scandinavian journal of trauma, resuscitation and emergency medicine·2025

No cyclin-dependent kinase (CDK) inhibitors are approved for cancer therapy due to challenges in achieving selective inhibition and functional redundancy. New strategies targeting multiple CDKs or protein interactions may offer therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinases (CDKs) are key regulators of the cell cycle and extensively targeted in anti-cancer drug design.
  • Despite significant research, no CDK inhibitor has gained regulatory approval for cancer therapy.
  • Challenges include achieving selective CDK inhibition and overcoming functional redundancy within the CDK system.

Purpose of the Study:

  • To explore the complexities of targeting cyclin-dependent kinases (CDKs) for cancer therapy.
  • To identify potential strategies for developing effective CDK inhibitors that address current limitations.
  • To evaluate alternative approaches beyond traditional ATP-competitive inhibition.

Main Methods:

  • Review of existing challenges in CDK inhibitor development.

Related Experiment Videos

  • Analysis of functional redundancy in CDK cell-cycle regulation.
  • Exploration of ATP-competitive and protein:protein interaction inhibitor strategies.
  • Consideration of computational and experimental drug design advancements.

    • Main Results:

    • Current CDK inhibitors often lack specificity, inhibiting multiple CDK family members.
    • Functional redundancy in CDK pathways complicates therapeutic targeting.
    • Developing inhibitors that target multiple CDKs or specific protein interactions is necessary.
    • Advances in drug design offer new possibilities for achieving desired inhibition profiles.

    Conclusions:

    • Achieving a therapeutically useful profile of CDK inhibition remains challenging but feasible.
    • Both ATP-competitive inhibitors and inhibitors of CDK-specific protein:protein interactions present viable therapeutic avenues.
    • Further research into novel inhibition strategies is crucial for advancing CDK-targeted cancer therapy.